Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.

Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, Woerther PL, Vozy A, Naigeon M, Nebot-Bral L, Desbois M, Simeone E, Mateus C, Boselli L, Grivel J, Soularue E, Lepage P, Carbonnel F, Ascierto PA, Robert C, Chaput N. · 2020

Read Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. by Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, Woerther PL, Vozy A, Naigeon M, Nebot-Bral L, Desbois M, Simeone E, Mateus C, Boselli L, Grivel J, Soularue E, Lepage P, Carbonnel F, Ascierto PA, Robert C, Chaput N. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7195489.txt.

Introduction

Coutzac and co-authors report that gut bacteria products in the blood can blunt a cancer immunotherapy. Their study appeared in Nature Communications. Gut microbes make short-chain fatty acids when they ferment dietary fiber. These compounds shape immune responses throughout the body. The team studied mice and patients treated with CTLA-4 blocking antibodies.

High blood levels of butyrate and propionate tracked with resistance to the treatment. Those patients also carried more regulatory T cells. The fatty acids weakened the immune activation the drug tries to spark. Memory T cell buildup after treatment stayed low. The results suggest diet and gut microbes can sway cancer therapy. Measuring these compounds might one day help predict who responds.

Catalog record

CREATORCoutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, Woerther PL, Vozy A, Naigeon M, Nebot-Bral L, Desbois M, Simeone E, Mateus C, Boselli L, Grivel J, Soularue E, Lepage P, Carbonnel F, Ascierto PA, Robert C, Chaput N.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7195489

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer By Clélia Coutzac, Jean-Mehdi Jouniaux, Angelo Paci, Julien Schmidt, Domenico Mallardo, Atmane Seck, Vahe Asvatourian, Lydie Cassard, Patrick Saulnier, Ludovic Lacroix, Paul-Louis Woerther, Aurore Vozy Published in: Nature Communications DOI: 10.1038/s41467-020-16079-x ABSTRACT Gut microbiota composition influences the clinical benefit of immune checkpoints in patients with advanced cancer but mechanisms underlying this relationship remain unclear. Molecular mechanism whereby gut microbiota influences immune responses is mainly assigned to gut microbial metabolites. Short-chain fatty acids (SCFA) are produced in large amounts in the colon through bacterial fermentation of dietary fiber. We evaluate in mice and in patients treated with anti-CTLA-4 blocking mAbs whether SCFA levels is related to clinical outcome. High blood butyrate and propionate levels are associated with resistance to CTLA-4 blockade and higher proportion of Treg cells. In mice, butyrate restrains anti-CTLA-4-induced up-regulation of CD80/CD86 on dendritic cells and ICOS on T cells, accumulation of tumor-specific T cells and memory T cells. In patients, high blood butyrate levels moderate ipilimumab-induced accumulation of memory and ICOS + CD4 + T cells and IL-2 impregnation. Altogether, these results suggest that SCFA limits anti-CTLA-4 activity. INTRODUCTION In the past ten years therapeutic strategies in oncology have been revolutionized by the use of immune checkpoint blocking antibodies. In clinical practice, CTLA-4 blockade using the therapeutic monoclonal antibody (mAb) ipilimumab (anti-CTLA-4) was approved as standalone or in combo with nivolumab (anti-PD-1) in patients with metastatic melanoma (MM)1–4. Approximately 20 and 60% of patients with MM have an objective clinical response with ipilimumab and with ipilimumab/nivolumab combination respectively. Recently, studies suggested that gut microbiota composition was associated with antitumor efficacy in patients with MM treated with anti-CTLA-45,6 and anti-PD-17 mAb. The composition of gut microbiota also seems to be associated with the risk to develop anti-CTLA-4-induced colitis in patient with MM6,8. These recent studies highlight specific bacteria associated with clinical response and/or toxicities. Especially, baseline gut microbiota enriched with Faecalibacterium and other Firmicutes was associated with beneficial clinical response to ipilimumab, anti-PD-1, and ipilimumab/anti-PD-1 therapy in melanoma patients6,7,9. Based on these independent works, it appears that Faecalibacterium might represent a major feature associated with clinical response in MM patients treated with immune checkpoints. However, scarce findings explain how the gut microbiota composition could have an impact on a distant tumor lesion. In mice, anti-CTLA-4 blocking mAb was shown to induce a dysbiosis favoring the translocation of commensal bacteria that might allow IL-12-secretion by dendritic cells (DCs) as well as the priming of commensal-specific Th1 cells that could migrate to the tumor and recognize tumor cells due to antigen mimicry5. Another mechanism was described in mice treated with anti-PD-L1, where specific bacteria (i.e., Bifidobacterium) was associated with an increase DC maturation leading to enhance CD8+ T cell priming and accumulation in the tumor beds under PD-L1 blockade conditions10. In patients with MM treated with anti-PD-1, enriched Faecalibacterium was linked to higher CD8+ T cell tumor infiltrate7. In addition to the direct effect of commensal bacteria on immune system, it is well known that some bacterial groups produce metabolites that have also immune properties11. These de novo synthesized metabolites include short-chain fatty acid (SCFA), mainly acetate (C2), propionate (C3) and butyrate (C4). SCFA mediate several functions especially providing energy to intestinal epithelial cells (IEC)12,13. SCFA also play a pivotal role on immune modulation11. Butyrate is well known to exert systemic anti-inflammatory activities by affecting immune cell migration, adhesion, cytokine expression as well as affecting cellular processes such as proliferation, activation, and apoptosis14. Considering previous results on the association between gut microbiota composition and clinical response and the effect of SCFA on the immune system, even at distant site, we hypothesized that anti-cancer response due to anti-CTLA-4 blockade may be influenced by systemic microbial SCFA. In this study, we demonstrate that microbial systemic SCFA (butyrate and propionate) influence anti-CTLA-4 anti-tumor effect in mice models and in patients with MM and treated with ipilimumab. RESULTS Microbiota composition and clinical outcomes in patients As previously analyzed and replicated with sequencing technology, baseline microbiota enriched in Faecalibacterium prausnitzii (F. prausnitzii) and other Firmicutes was associated with better outcome in a French cohort of 26 MM patients treated with ipilimumab6. In the present study, among the fifty MM patients included, 16S rDNA analyses were performed on 38 fecal samples at baseline (V1) (Supplementary information and Supplementary Tables 1, 2 and 3). We analysed the main genera composition (Fig. 1a). Genera linked to long-term clinical benefit (LTB; progression free survival > 6 months) were Faecalibacterium and Gemminger (Fig. 1b). High proportions of Bacteroides could be found in patients with poor clinical benefit but no statistical significance was reached compared to patients with LTB (Fig. 1b). Other genera were not associated with clinical outcome (Fig. 1b). Altogether, Faecalibacterium might represent a good surrogate marker of LTB. Considering ipilimumab-induced colitis, a tendency for higher proportions of Faecalibacterium, Lachnospiracae and Gemminger, and lower proportion of Prevotella were observed in patients that develop ipilimumab-related colitis even though not significant (Supplementary Fig. 1). High relative abundance of Faecalibacterium at baseline was linked to overall survival (OS) over than 18 months (Fig. 1c). Kaplan–Meier analyses of patients classified into two groups according to median value of the abundance of Faecalibacterium, showed that high baseline Faecalibacterium was associated with longer progression free survival (PFS) (Fig. 1d). Note that Faecalibacterium, Gemminger6, Roseburia as well as Bifidobacterium genera described in another study as associated with clinical efficacy after anti-PD-L1 treatment10 were positively correlated whereas Bacteroides genera was inversely correlated to Faecalibacterium (Supplementary Fig. 2).Fig. 1Baseline gut microbiota composition in patients with MM.a Relative abundance of dominant (>1% of total reads) gut microbial genera are represented for each patient at V1 (baseline, n = 38). b Histograms of relative abundance of eight genera at baseline between poor (PB) and long-term clinical benefit (LTB) patients. Mann–Whitney two-tailed tests were used. p-values are indicated on each graph. c Histograms of relative abundance of Faecalibacterium according to overall survival (OS over 18 months (OS > 18 m) and OS under 18 months (OS < 18 m)) in patients. Mann–Whitney two-tailed tests were used. p-values are indicated on the graph. d, Kaplan–Meier curve of progression-free survival (PFS) of patients classified into two groups according to the median relative abundance of Faecalibacterium (n = 38). Log-rank (mantel-cox) test was used. e Pearson correlation between the relative abundance of Faecalibacterium assessed by 16S rDNA analysis (% of total reads NGS) and Q-PCR (% Q-PCR) analyses on feces at baseline (n = 24). r and p values are indicated on each graph. ns, not significant. Then, we applied quantitative PCR (Q-PCR) analyses on baseline feces in the cohort for F. prausnitzii, Bacteroides fragilis (B. fragilis) and Escherichia coli (E. coli) (Supplementary Table 1 and 3). Quantitative-PCR and 16S rDNA analysis data were highly correlated (Fig. 1e and Supplementary Fig. 3). All patients with an OS longer than 18 months showed higher proportions of F. prausnitzii contrary to B. fragilis (Fig. 2a). Interestingly, abundance of F. prausnitzii and bacterial load were correlated together (Supplementary Fig. 4) and were linked to improve PFS in patients (Fig. 2b). No such correlation and difference could be observed for B. fragilis5 or

Read the complete text